SEARCH

SEARCH BY CITATION

References

  • 1
    Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci 1980; 12: 1- 58.
  • 2
    Targher G. Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer — a narrative review. Clin Chem Lab Med 2010; 48: 147- 157.
  • 3
    Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. HEPATOLOGY 2009; 50: 1403- 1411.
  • 4
    Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136: 477- 485.
  • 5
    Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429- 2441.
  • 6
    Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. HEPATOLOGY 2011; 54: 396- 405.
  • 7
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 472- 492.
  • 8
    Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. HEPATOLOGY 2005; 42: 282- 292.
  • 9
    Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P, et al. The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol 2011; 46: 1427- 1436.
  • 10
    Coban S, Idilman R, Erden E, Tuzun A. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C. Hepatogastroenterology 2011; 58: 1301- 1306.
  • 11
    Moraes Coelho HS, Villela-Nogueira CA. Predictors of response to chronic hepatitis C treatment. Ann Hepatol 2010; 9( Suppl): 54- 60.
  • 12
    Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005; 39: 728- 730.
  • 13
    Bergmann JF, Vrolijk JM, van der Schaar P, Vroom B, van Hoek B, van der Sluys V, et al. Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007; 27: 1217- 1225.
  • 14
    Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res 2010; 40: 251- 260.
  • 15
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399- 401.
  • 16
    Agundez JA, Garcia-Martin E, Maestro ML, Cuenca F, Martinez C, Ortega L, et al. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis c virus-induced liver disease. PLoS One 2012; 7: e37998.
  • 17
    Hwang SJ, Luo JC, Lai CR, Chu CW, Tsay SH, Lu CL, et al. Clinical, virologic and pathologic significance of elevated serum gamma-glutamyl transpeptidase in patients with chronic hepatitis C. Chung Hua I Hsueh Tsa Chih (Taipei) 2000; 63: 527- 535.
  • 18
    Paolicchi A, Marchi S, Petruccelli S, Ciancia E, Malvaldi G, Pompella A. Gamma-glutamyltransferase in fine-needle liver biopsies of subjects with chronic hepatitis C. J Viral Hepat 2005; 12: 269- 273.
  • 19
    Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat 2006; 13: 303- 310.
  • 20
    Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2004; 19: 314- 318.
  • 21
    Uchimura Y, Sata M, Kage M, Abe H, Tanikawa K. A histopathological study of alcoholics with chronic HCV infection: comparison with chronic hepatitis C and alcoholic liver disease. Liver 1995; 15: 300- 306.
  • 22
    Valenti L, Rumi M, Galmozzi E, Aghemo A, Del MB, De NS, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. HEPATOLOGY 2011; 53: 791- 799.
  • 23
    Vardar R, Vardar E, Demiri S, Sayhan SE, Bayol U, Yildiz C, et al. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis? Hepatogastroenterology 2009; 56: 1459- 1465.
  • 24
    Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.
  • 25
    Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002; 36: 986- 992.
  • 26
    Forns X, Ampurdanes S, Sanchez-Tapias JM, Guilera M, Sans M, Sanchez-Fueyo A, et al. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001; 35: 265- 271.
  • 27
    Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930- 938.
  • 28
    Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138: 136- 146.
  • 29
    Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. HEPATOLOGY 2008; 48: 129- 136.
  • 30
    Van HM, Jassem W, Walldius G, Fentiman IS, Hammar N, Lambe M, et al. Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons — the Swedish AMORIS study. Eur J Cancer 2011; 47: 2033- 2041.
  • 31
    Rauchenzauner M, Kountchev J, Ulmer H, Pechlaner C, Bellmann R, Wiedermann CJ, et al. Disturbances of electrolytes and blood chemistry in acute alcohol intoxication. Wien Klin Wochenschr 2005; 117: 83- 91.
  • 32
    Holme J, Dawkins PA, Stockley EK, Parr DG, Stockley RA. Studies of gamma-glutamyl transferase in alpha-1 antitrypsin deficiency. COPD 2010; 7: 126- 132.
  • 33
    Fraser A, Harris R, Sattar N, Ebrahim S, Davey SG, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009; 32: 741- 750.
  • 34
    Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007; 27: 2729- 2735.
  • 35
    Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998; 21: 732- 737.
  • 36
    Breitling LP, Claessen H, Drath C, Arndt V, Brenner H. Gamma-glutamyltransferase, general and cause-specific mortality in 19,000 construction workers followed over 20 years. J Hepatol 2011; 55: 594- 601.
  • 37
    Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem 2007; 53: 940- 946.
  • 38
    Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol 1989; 257: L163- L173.
  • 39
    Zhang H, Forman HJ, Choi J. Gamma-glutamyl transpeptidase in glutathione biosynthesis. Methods Enzymol 2005; 401: 468- 483.
  • 40
    Dominici S, Paolicchi A, Corti A, Maellaro E, Pompella A. Prooxidant reactions promoted by soluble and cell-bound gamma-glutamyltransferase activity. Methods Enzymol 2005; 401: 484- 501.
  • 41
    Zhang H, Forman HJ. Redox regulation of gamma-glutamyl transpeptidase. Am J Respir Cell Mol Biol 2009; 41: 509- 515.
  • 42
    Liu RM, Hu H, Robison TW, Forman HJ. Differential enhancement of gamma-glutamyl transpeptidase and gamma-glutamylcysteine synthetase by tert-butylhydroquinone in rat lung epithelial L2 cells. Am J Respir Cell Mol Biol 1996; 14: 186- 191.
  • 43
    Lee DH, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 2005; 178: 327- 330.
  • 44
    Ortega E, Koska J, Salbe AD, Tataranni PA, Bunt JC. Serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab 2006; 91: 1419- 1422.
  • 45
    Lok AS, Everhart JE, Chung RT, Kim H-Y, Everson GT, Hoefs J, et al. Evolution of hepatic steatosis in patients with advanced hepatitiis C: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial (HALT-C). HEPATOLOGY 2009; 49: 1828- 1837.
  • 46
    Tanaka K, Tokunaga S, Kono S, Tokudome S, Akamatsu T, Moriyama T, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998; 27: 438- 443.
  • 47
    Casiglia E, Spolaore P, Ginocchio G, Ambrosio GB. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993; 9: 293- 297.
  • 48
    Poikolainen K, Vartiainen E. Determinants of gamma-glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee. Am J Epidemiol 1997; 146: 1019- 1024.
  • 49
    Lee DH, Zacharski LR, Jacobs DR Jr. Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress-related disease outcomes. Am Heart J 2006; 151: 1247.